BiotechTube

E2007

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine Prophylaxis

Conditions

Migraine Prophylaxis

Trial Timeline

Jan 1, 2005 → Jun 1, 2006

NCT ID
NCT00154063

About E2007

E2007 is a phase 2 stage product being developed by Eisai for Migraine Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT00154063. Target conditions include Migraine Prophylaxis.

What happened to similar drugs?

20 of 20 similar drugs in Migraine Prophylaxis were approved

Approved (20) Terminated (1) Active (0)
✅Galcanezumab + ErenumabEli LillyApproved
✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
✅tramadol HCl/acetaminophenJohnson & JohnsonApproved
✅topiramate; almotriptan malateJohnson & JohnsonApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mgAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT03201900Phase 3Completed
NCT02116907Phase 1Completed
NCT00849212Phase 2Completed
NCT00592904Phase 2/3Completed
NCT00451633Phase 2Withdrawn
NCT00427011Phase 2Terminated
NCT00360412Phase 3Terminated
NCT00286897Phase 3Completed
NCT00165789Phase 2Completed
NCT00154063Phase 2Completed

Competing Products

20 competing products in Migraine Prophylaxis

See all competitors
ProductCompanyStageHype Score
DFN-11Dr. Reddy's LaboratoriesPhase 2
32
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)Dr. Reddy's LaboratoriesPhase 1
26
DFN-11Dr. Reddy's LaboratoriesPhase 3
37
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)Dr. Reddy's LaboratoriesPhase 2
32
DFN-15Dr. Reddy's LaboratoriesPhase 2
32
ABP-450AEON BiopharmaPhase 2
17
Lasmiditan + PlaceboEli LillyPhase 3
40
Placebo + LY2300559Eli LillyPhase 2
27
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
29
ABP-450 + PlaceboAEON BiopharmaPhase 2
25
Lasmiditan + PlaceboEli LillyPhase 2
35
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Galcanezumab + ErenumabEli LillyApproved
43
Aricept (donepezil hydrochloride)EisaiPhase 2
35
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
43
Galcanezumab + PlaceboEli LillyPhase 3
40
Lasmiditan + PlaceboEli LillyPhase 2
35
Galcanezumab + PlaceboEli LillyPhase 3
40